We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Lung Cancer

Expert Opinion / Cases · February 01, 2021

Optimal First-Line Precision Therapy for Adenocarcinoma

Written by
Michael J. Grant MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Swapan Kumar   Nath

    I think immunotherapy (pembrolizumab) plus chemotherapy ( platinum plus pemitrexate) would be the best first choice.


  • Jean-Yves Douillard

    I would suggest Pembrolizumab + chemotherapy (Platinum Pemetrexed), my main rational for adding chemo here is the presence of liver metastasis that respond poorly to immunotherapy and are a bad prognostic factor I would also remember the Kras G12D mutation and look for a clinical trial (if any!) with a targeted agent in later line.


  • Mahmoud  Soliman

    pembro + chemo... Kras g12c eligable for sotorasib not g12d


  • Sep 21, 2021

    Pending Moderator approval.
    Delete

Further Reading